Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription 27.04.2026 1 Am J Hematol 1 Blood 1 Br J Haematol 1 Cancer Lett 3 Haematologica 2 Int J Cancer 1 J Clin Oncol 8 Leuk Lymphoma 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. GODTFREDSEN SJ, Baech J, Andersen MP, Yonis H, et al
   Long-Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators.
   Am J Hematol. 2026 Apr 18. doi: 10.1002/ajh.70331.
   PubMed         Abstract available
   
   

   
   Blood

2. BARIBOLOKA KT, Serrano-Saenz S, Savcigil DP, Spoeck S, et al
   Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.
   Blood. 2026 Apr 23:blood.2026033320. doi: 10.1182/blood.2026033320.
   PubMed         Abstract available
   
   

   
   Br J Haematol

3. DINGLI S, Rothweiler P, Corraes AMS, Atallah-Yunes A, et al
   Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.
   Br J Haematol. 2026 Apr 21. doi: 10.1111/bjh.70502.
   PubMed         Abstract available
   
   

   
   Cancer Lett

4. BASAPPA J, Goldman AR, Lobello C, Wang S, et al
   Mitochondrial ACSS1 links acetate metabolism to pyrimidine biosynthesis in nutrient-stressed B-cell lymphomas.
   Cancer Lett. 2026;649:218488.
   PubMed         Abstract available
   
   

   
   Haematologica

5. LUTTERBECK C, Kaufman D, Bolen CR, Shin M, et al
   Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.
   Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.289111.
   PubMed         Abstract available
   
   
6. BASILE G, Neuville A, Martineau D, Delapierre B, et al
   Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.
   Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.300289.
   PubMed         Abstract available
   
   
7. PAGES-GELI C, Medina-Gil D, Fernandez-Guzman P, Hernandez C, et al
   Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.
   Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.300015.
   PubMed         Abstract available
   
   

   
   Int J Cancer

8. MATOS A, Cawthorn WP, Marinho-Dias J, Ramalheira S, et al
   Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis.
   Int J Cancer. 2026 Apr 20. doi: 10.1002/ijc.70480.
   PubMed         Abstract available
   
   
9. WANG H, Li J, Cao L, Zhang Y, et al
   Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.
   Int J Cancer. 2026 Apr 18. doi: 10.1002/ijc.70507.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

10. MEHTA-SHAH N, Zinzani PL, Jacobsen ED, Zain J, et al
    Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2026 Apr 22:101200JCO2503120. doi: 10.1200/JCO-25-03120.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

11. HU L, Lu B, Wei X, Wang Y, et al
    A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2026 Apr 24:1-8. doi: 10.1080/10428194.2026.2654977.
    PubMed         Abstract available
    
    
12. ZIELSKE SP, Fernandez-Valdivia R
    Molecular deconstruction of anaplastic large cell Lymphoma (ALCL).
    Leuk Lymphoma. 2026 Apr 22:1-3. doi: 10.1080/10428194.2026.2661081.
    PubMed        
    
    
13. MOON IJ, Choi J, Jung JM, Won CH, et al
    Clinicopathological factors associated with the prognosis and relapse of primary cutaneous marginal zone lymphoma: a retrospective cohort study.
    Leuk Lymphoma. 2026 Apr 21:1-9. doi: 10.1080/10428194.2026.2656942.
    PubMed         Abstract available
    
    
14. CAMPBELL BA, Minson A, Brown RJ, Chin CK, et al
    Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2026;67:1100-1108.
    PubMed         Abstract available
    
    
15. TARANTINI G, Miccolis RM, Arcuti E, Buquicchio C, et al
    A new era for transplant-ineligible R/R LBCL patients: what's changing?
    Leuk Lymphoma. 2026;67:997-1004.
    PubMed         Abstract available
    
    
16. MADDOCKS K, Tracey M, Winfree KB, Hall Panjic E, et al
    Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.
    Leuk Lymphoma. 2026;67:1055-1065.
    PubMed         Abstract available
    
    
17. OHNO H, Maekawa F, Hayashida M, Nakagawa M, et al
    t(14;19)(q32;q13) breakpoints telomeric to BCL3 on 19q13.32 in B-cell lymphomas other than chronic lymphocytic leukemia and long-range structures of der(19)t(14;19) based on optical genome mapping.
    Leuk Lymphoma. 2026 Feb 22:1-11. doi: 10.1080/10428194.2026.2633186.
    PubMed         Abstract available
    
    
18. RALLI S, Jones SJ, Leach S, Lynch HJ, et al
    Identifying genes and pathways in familial lymphoid cancers using whole exome sequencing.
    Leuk Lymphoma. 2026;67:1014-1028.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

19. LEVIS M, Solidoro P, Giglioli FR, Gallio E, et al
    Continuous positive airway pressure as an alternative to deep-inspiration breath holding for mediastinal lymphoma radiotherapy.
    Radiother Oncol. 2026;220:111539.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum